Background: Lung cancer is one of the most fatal chronic diseases in the field of respiratory medicine. The
purpose of this paper is to address the side effects of conventional treatment strategies and to report the findings of till date
drug nanocarriers researches performed for lung cancer therapy. This review also highlights the outstanding results of
several researches employing pulmonary delivery system of nano-based drug formulations suitable for lung cancer.
Objective: Summarizing the advances made in the field of nanotechnology-based lung cancer management.
Methods: We systematically searched for research literature using a well-framed review question and presented data in
the tabular forms for readers’ convenience.
Results: Sixty-four papers were included in the review, the majority of which represent latest researches in the field of
nanoparticle-based drug delivery for lung cancer therapy. Conventional treatment strategies for lung cancer lack specificity
and are limited by undesirable toxicities in normal cells, as well as a high rate of recurrence. Intervention of
nanotechnology has revolutionized the therapy of lung cancer upto a great extent by overcoming the current constraints
in conventional therapies. Pulmonary delivery of nano-based drug formulations has resulted in potentially more effective
and advanced lung cancer therapy.
Conclusion: Several nanoscale drug delivery systems for lung cancer treatment are at present in clinical trials and
some of them already exist in commercially available forms in the marketplace. However, although nanoscale drug
carriers for lung cancer treatment have demonstrated stupendous therapeutic potential at both preclinical and clinical
trials, but there are still many limitations to be solved.